Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
03/18/19Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 18th at 8:30 a.m. EDT CINCINNATI--(BUSINESS WIRE)--Mar. 18, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Company’s TIME-2b study, a Phas... 
Printer Friendly Version
03/05/19Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) Expected in March 2019 Conference Call and Webcast Today, March 5th at 8:30 a.m. EST CINCINNATI--(BUSINESS WIRE)--Mar. 5, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabe... 
Printer Friendly Version
02/26/19Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019
CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2019-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that its fourth quarter and full year 2018 financial results will be released before the market opens on Tuesday, March 5, 2019. Following the release, the Company will host a live conference call and webcast at 8:30 a.m.... 
Printer Friendly Version
01/17/19Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
CINCINNATI--(BUSINESS WIRE)--Jan. 17, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-prolife... 
Printer Friendly Version